Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group insider Patrick H. Conway, Chief Executive Officer of Optum, reported an increase in his holdings of company common stock through dividend equivalents on restricted stock units. On 12/16/2025, he acquired 67.721 shares at a price of $0, reflecting stock dividends credited on his outstanding restricted stock units. After this transaction, he beneficially owned 10,603.915 shares of UnitedHealth Group common stock in direct ownership. The filing notes that these dividend equivalents are subject to the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest.
UnitedHealth Group reported an insider equity update for its Chief Financial Officer. On 12/16/2025, the CFO acquired 70.042 shares of UnitedHealth Group common stock at a price of $0. These shares represent dividend equivalents credited on outstanding restricted stock units, meaning additional shares were granted in lieu of cash dividends on those units.
Following this transaction, the CFO beneficially owns 10,661.941 shares of UnitedHealth Group common stock in direct ownership. The dividend-equivalent shares are subject to the same vesting and forfeiture conditions as the underlying restricted stock units.
UnitedHealth Group Inc. director Timothy P. Flynn reported a small increase in his holdings of the company’s common stock through an insider transaction dated 12/16/2025. The filing shows an acquisition of 65 shares of common stock at a stated price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and follow the same terms as the underlying units.
After this transaction, Flynn beneficially owned 9,875 shares of UnitedHealth Group common stock directly and 6,033 shares indirectly through a trust. The form is filed for one reporting person and is signed by an attorney-in-fact on Flynn’s behalf.
UnitedHealth Group director reports additional stock via dividend equivalents. Director Michele J. Hooper reported acquiring 249 shares of UnitedHealth Group common stock on 12/16/2025 at a price of $0 per share. These shares represent dividend equivalents paid on vested deferred stock units and are immediately vested, carrying the same terms as the underlying deferred stock units. Following this transaction, she beneficially owns 41,126 shares of UnitedHealth Group common stock in direct ownership.
UnitedHealth Group director reports small stock-related award. A UnitedHealth Group Inc. director reported receiving 13 shares of common stock on 12/16/2025 as dividend equivalents on vested deferred stock units, at a stated price of $0. These dividend equivalents vest immediately and follow the same terms as the underlying deferred stock units. After this transaction, the director holds 3,034 UnitedHealth Group shares directly, and additional indirect holdings of 2,146 shares through a revocable trust, 45 shares through one trust, and 55 shares through another trust.
UnitedHealth Group’s Chief Accounting Officer, Thomas E. Roos, reported an automatic increase in his holdings of company common stock. On 12/16/2025, he acquired 23.408 shares of common stock at a price of $0, coded as an acquisition, bringing his total directly held beneficial ownership to 29,642.927 shares.
The filing explains that these additional shares represent dividend equivalents credited on outstanding restricted stock units. These dividend equivalents follow the same vesting conditions as the underlying restricted stock units and will be forfeited if those units do not vest, meaning the added shares are still subject to performance or service-based requirements.
UnitedHealth Group Inc. (UNH) director reports initial ownership in a Form 3 filed under Section 16. As of the event date of 11/18/2025, the reporting person lists beneficial ownership of 0 shares of UnitedHealth Group common stock, held directly. No derivative securities are reported in the derivative securities table.
The form is filed by one reporting person in the capacity of director. A power of attorney is on file, with the Form 3 signed by Faraz A. Choudhry as attorney-in-fact for Scott M. Gottlieb.
UnitedHealth Group Incorporated reported that its Board of Directors has appointed Scott Gottlieb, M.D. as an independent director, effective immediately. He has not yet been assigned to any Board committees.
Dr. Gottlieb is a former FDA commissioner who served from 2017 to 2019, where he focused on transparency, patient safety, medical innovation, pharmaceutical competition, the opioid crisis and youth tobacco use. He has also held positions at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee, and is a physician, a member of the National Academy of Medicine, a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates.
Dr. Gottlieb currently serves on the boards of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. He will receive the company’s standard compensation for non-employee directors as described in UnitedHealth Group’s 2025 proxy statement, and the company will enter into its standard indemnification agreement with him.
UnitedHealth Group amended its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of the change is to reflect updates to the Company’s registered office and registered agent in the State of Delaware.
A complete copy of the Bylaws, as amended, is filed as Exhibit 3.1.
UnitedHealth Group announced that senior leaders will participate in an interview at the UBS Global Healthcare Conference 2025. The session is scheduled for Monday, November 10, 2025, at 8:45 a.m. Eastern Time.
A live audio webcast will be accessible via the Investor Relations section of the company’s website. The disclosure is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Securities Exchange Act of 1934.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
